Analysts at D. Boral Capital initiated coverage on shares of Tevogen Bio (NASDAQ:TVGN - Get Free Report) in a research report issued on Tuesday,Benzinga reports. The firm set a "buy" rating and a $10.00 price target on the stock.
Tevogen Bio Trading Down 7.8 %
TVGN opened at $1.18 on Tuesday. The firm has a fifty day moving average price of $1.35 and a 200 day moving average price of $1.14. Tevogen Bio has a 1 year low of $0.26 and a 1 year high of $8.49.
Hedge Funds Weigh In On Tevogen Bio
Institutional investors and hedge funds have recently modified their holdings of the business. Barclays PLC boosted its position in Tevogen Bio by 39.2% during the fourth quarter. Barclays PLC now owns 45,600 shares of the company's stock worth $48,000 after purchasing an additional 12,847 shares in the last quarter. Northern Trust Corp lifted its position in shares of Tevogen Bio by 13.0% during the 4th quarter. Northern Trust Corp now owns 118,415 shares of the company's stock valued at $122,000 after buying an additional 13,595 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Tevogen Bio by 74.2% in the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock valued at $40,000 after acquiring an additional 16,695 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Tevogen Bio in the 4th quarter worth $38,000. Finally, XTX Topco Ltd purchased a new position in Tevogen Bio during the fourth quarter valued at $55,000.
About Tevogen Bio
(
Get Free Report)
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tevogen Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tevogen Bio wasn't on the list.
While Tevogen Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
